No Data
No Data
Mizuho Securities Raises Quest Diagnostics' Price Target to $160 From $155
Maintaining Neutral Hold on Quest Diagnostics Amid Modest Growth and Pending Strategic Insights
Decoding Quest Diagnostics Inc (DGX): A Strategic SWOT Insight
Becton, Dickinson Partners With Quest Diagnostics on Flow Cytometry-Based Companion Diagnostics
Express News | BD: Offerings Will Include Exploratory Panel Development, Manufacturing & Distribution of FDA-Approved Diagnostic Kits
Express News | BD: Co, Quest Diagnostics to Develop, Manufacture and Commercialize Flow Cytometry-Based Companion Diagnostics
No Data